(Q37214661)

19 August 2017

1 reference

title

Do effectiveness ("real world") studies on antipsychotics tell us the real truth? (English)

1 reference

19 August 2017

1

Hans-Jürgen Möller

1 reference

19 August 2017

language of work or name

1 reference

11 July 2008

1 reference

European Archives of Psychiatry and Clinical Neuroscience

19 August 2017

published in

1 reference

19 August 2017

volume

258

1 reference

19 August 2017

issue

5

1 reference

19 August 2017

page(s)

257-270

1 reference

https://scigraph.springernature.com/pub.10.1007/s00406-008-0812-0

19 August 2017

exact match

0 references

cites work

Quality of life in schizophrenia: a comparison of instruments. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia

1 reference

https://api.crossref.org/works/10.1007%2FS00406-008-0812-0

Prophylactic antiparkinson drug use: II. Withdrawal after long-term maintenance therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-008-0812-0

The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-008-0812-0

Methylphenidate response, psychopathology and tardive dyskinesia as predictors of relapse in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-008-0812-0

A neurodevelopmental approach to the classification of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-008-0812-0

The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-008-0812-0

World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia

21 January 2018

1 reference

12 December 2020

Haloperidol dose when used as active comparator in randomized controlled trials with atypical antipsychotics in schizophrenia: comparison with officially recommended doses

1 reference

12 December 2020

[Problems of evidence-based medicine in psychopharmacotherapy: problems of evidence grading and of the evidence basis for complex clinical decision making]

1 reference

12 December 2020

Sulpiride: an antipsychotic with selective dopaminergic antagonist properties

1 reference

12 December 2020

Influence of atypical neuroleptics on executive functioning in patients with schizophrenia: a randomized, double-blind comparison of olanzapine vs. clozapine

1 reference

12 December 2020

Selection Bias in Clinical Trials With Antipsychotics

1 reference

12 December 2020

World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia

1 reference

12 December 2020

Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia.

1 reference

12 December 2020

Effectiveness of switching antipsychotic medications

1 reference

12 December 2020

Predictors of outcome in schizophrenia.

1 reference

12 December 2020

Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics

1 reference

12 December 2020

World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia

1 reference

12 December 2020

Are the new antipsychotics no better than the classical neuroleptics? The problematic answer from the CATIE study

1 reference

12 December 2020

A randomized, controlled comparison of the efficacy and tolerability of low and high doses of haloperidol in the treatment of first-episode psychosis

1 reference

12 December 2020

Discontinuing and switching antipsychotic medications: understanding the CATIE schizophrenia trial.

1 reference

12 December 2020

Practice guideline for the treatment of patients with schizophrenia, second edition.

1 reference

12 December 2020

Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial.

1 reference

12 December 2020

Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy

1 reference

12 December 2020

Placebo-controlled trials in major depression are necessary and ethically justifiable: how to improve the communication between researchers and ethical committees.

1 reference

12 December 2020

Receptor-binding profiles of antipsychotics: clinical strategies when switching between agents.

1 reference

12 December 2020

Placebo-controlled studies in depression: necessary, ethical and feasible

1 reference

12 December 2020

[Meta-analyses. A tool for maximizing therapy study evidence?]

1 reference

12 December 2020

[Are placebo controlled studies on the proof of effectiveness of antidepressants necessary?].

1 reference

12 December 2020

Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia

1 reference

12 December 2020

The MOS 36-ltem Short-Form Health Survey (SF-36)

1 reference

12 December 2020

Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study

1 reference

12 December 2020

Current issues in schizophrenia: overview of patient acceptability, functioning capacity and quality of life

1 reference

12 December 2020

Should the CATIE study be a wake-up call?

1 reference

12 December 2020

Schizophrenics with small P300: a subgroup with a neurodevelopmental disturbance and a high risk for tardive dyskinesia?

1 reference

12 December 2020

Anticholinergic agents for prophylaxis of neuroleptic-induced dystonic reactions: a prospective study

1 reference

12 December 2020

Drug and sociotherapy in the aftercare of schizophrenic patients. One-year relapse rates

1 reference

12 December 2020

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

1 reference

12 December 2020

Rating depressed patients: observer- vs self-assessment

1 reference

12 December 2020

Quality of life in psychiatry: a systematic contribution to construct validation and the development of the integrative assessment tool "modular system for quality of life".

1 reference

12 December 2020

Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol

1 reference

12 December 2020

Double-blind, randomized comparison of olanzapine versus fluphenazine in the long-term treatment of schizophrenia

1 reference

12 December 2020

Addressing the limitations of the CATIE study

1 reference

12 December 2020

Amisulpride: limbic specificity and the mechanism of antipsychotic atypicality

1 reference

12 December 2020

Interpreting the efficacy findings in the CATIE study: what clinicians should know.

1 reference

12 December 2020

Switching antipsychotics: an updated review with a focus on quetiapine

1 reference

12 December 2020

Sulpiride for schizophrenia

1 reference

12 December 2020

Standardised rating scales in psychiatry: methodological basis, their possibilities and limitations and descriptions of important rating scales

1 reference

12 December 2020

Reliability and validity of Quality of Life assessed by the Short-Form 36 and the Modular System for Quality of Life in patients with schizophrenia and patients with depression

1 reference

12 December 2020

New antipsychotics, compliance, quality of life, and subjective tolerability--are patients better off?

1 reference

12 December 2020

Comparative effectiveness of antipsychotic drugs. A commentary on: Cost Utility Of The Latest Antipsychotic Drugs In Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE).

1 reference

12 December 2020

Comparing the sensitivity of generic effectiveness measures with symptom improvement in persons with schizophrenia.

1 reference

12 December 2020

Outcomes, costs, and policy caution. A commentary on: the Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1)

1 reference

12 December 2020

Comparative effectiveness of second-generation antipsychotics and haloperidol in acute schizophrenia.

1 reference

12 December 2020

Evaluation of the need for prophylactic antiparkinsonian medication in psychotic patients treated with neuroleptics

1 reference

12 December 2020

The relationship between symptomatic remission and neuropsychological improvement in schizophrenia patients switched to treatment with ziprasidone

1 reference

12 December 2020

Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).

1 reference

12 December 2020

Comparison between risperidone, olanzapine, and clozapine in the management of chronic schizophrenia: a naturalistic prospective 12-week observational study.

1 reference

12 December 2020

Conventional versus atypical neuroleptics: subjective quality of life in schizophrenic patients.

1 reference

12 December 2020

Subjective effects of antipsychotic treatment

1 reference

12 December 2020

Switching elderly chronic psychotic patients to olanzapine.

1 reference

12 December 2020

The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome

1 reference

12 December 2020

Changes in perceived health and functioning as a cost-effectiveness measure for olanzapine versus haloperidol treatment of schizophrenia.

1 reference

12 December 2020

Incidence of tardive dyskinesia in first-episode psychosis patients treated with low-dose haloperidol

1 reference

12 December 2020

Understanding the results of CATIE in the context of the field.

1 reference

12 December 2020

A comparison of olanzapine versus risperidone for the treatment of schizophrenia: a meta-analysis of randomised clinical trials

1 reference

12 December 2020

Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic

1 reference

12 December 2020

Subjective well-being and quality of life under atypical antipsychotic treatment

1 reference

12 December 2020

Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment

1 reference

12 December 2020

Commentary on the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE).

1 reference

12 December 2020

Benztropine prophylaxis of dystonic reactions

1 reference

12 December 2020

Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials

1 reference

12 December 2020

The relationship between quality of life and clinical efficacy from a randomized trial comparing olanzapine and ziprasidone.

1 reference

12 December 2020

Anticholinergic medication for neuroleptic-induced tardive dyskinesia

1 reference

12 December 2020

A Ser9Gly polymorphism in the dopamine D3 receptor gene (DRD3) and event-related P300 potentials

1 reference

12 December 2020

Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial

1 reference

12 December 2020

10.1007/S00406-008-0812-0

Identifiers

DOI

1 reference

19 August 2017

1 reference